A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
Active, not recruiting · Phase 2 · NCT02065011
Conditions: Usher's Syndrome
At a glance
- Research payments reported, 2025
- $6,274
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 9
About the trial
- Sponsor
- Sanofi
- Tested
- Blood draw for the laboratory assessment (drug)
- Dates
- Started 2013-09-12; completion 2031-06-13
- Results posted
- Not yet
Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
From ClinicalTrials.gov, last updated 2026-01-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $6,274 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.